Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

Related Articles by Review for PubMed (Select 22807375)

1.

Differentiating between models of epothilone binding to microtubules using tubulin mutagenesis, cytotoxicity, and molecular modeling.

Entwistle RA, Rizk RS, Cheng DM, Lushington GH, Himes RH, Gupta ML Jr.

ChemMedChem. 2012 Sep;7(9):1580-6. doi: 10.1002/cmdc.201200286. Epub 2012 Jul 16.

2.
3.

Discovery and development of the epothilones : a novel class of antineoplastic drugs.

Reichenbach H, Höfle G.

Drugs R D. 2008;9(1):1-10. Review.

PMID:
18095749
4.

Efficacy and safety of ixabepilone, a novel epothilone analogue.

Pivot X, Dufresne A, Villanueva C.

Clin Breast Cancer. 2007 Apr;7(7):543-9. Review.

PMID:
17509162
5.

Epothilone B and its analogs - a new family of anticancer agents.

Altmann KH.

Mini Rev Med Chem. 2003 Mar;3(2):149-58. Review.

PMID:
12570848
6.

Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.

Andreopoulou E, Muggia F.

Clin Breast Cancer. 2008 Mar;8 Suppl 2:S54-60. Review.

PMID:
18637400
7.

Structural comparison of the interaction of tubulin with various ligands affecting microtubule dynamics.

Stec-Martyna E, Ponassi M, Miele M, Parodi S, Felli L, Rosano C.

Curr Cancer Drug Targets. 2012 Jul;12(6):658-66. Review.

PMID:
22385515
8.

The biology and medicinal chemistry of epothilones.

Wartmann M, Altmann KH.

Curr Med Chem Anticancer Agents. 2002 Jan;2(1):123-48. Review.

PMID:
12678754
9.

Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.

Fojo T, Menefee M.

Ann Oncol. 2007 Jul;18 Suppl 5:v3-8. Review.

10.

Microtubules and resistance to tubulin-binding agents.

Kavallaris M.

Nat Rev Cancer. 2010 Mar;10(3):194-204. doi: 10.1038/nrc2803. Epub 2010 Feb 11. Review. Erratum in: Nat Rev Cancer. 2010 Apr;10(4):309.

PMID:
20147901
11.
12.

The binding sites of microtubule-stabilizing agents.

Field JJ, Díaz JF, Miller JH.

Chem Biol. 2013 Mar 21;20(3):301-15. doi: 10.1016/j.chembiol.2013.01.014. Review.

13.

Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.

Fumoleau P, Coudert B, Isambert N, Ferrant E.

Ann Oncol. 2007 Jul;18 Suppl 5:v9-15. Review.

14.

What tubulin drugs tell us about microtubule structure and dynamics.

Amos LA.

Semin Cell Dev Biol. 2011 Dec;22(9):916-26. doi: 10.1016/j.semcdb.2011.09.014. Epub 2011 Oct 5. Review.

PMID:
22001382
15.

Physiochemical aspects of tubulin-interacting antimitotic drugs.

Correia JJ, Lobert S.

Curr Pharm Des. 2001 Sep;7(13):1213-28. Review.

PMID:
11472263
16.

Preclinical discovery of ixabepilone, a highly active antineoplastic agent.

Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G.

Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66. doi: 10.1007/s00280-008-0724-8. Epub 2008 Mar 18. Review.

PMID:
18347795
17.

Microtubules: an overview.

Wade RH.

Methods Mol Med. 2007;137:1-16. Review.

PMID:
18085218
18.

Peloruside, laulimalide, and noscapine interactions with beta-tubulin.

Gajewski MM, Alisaraie L, Tuszynski JA.

Pharm Res. 2012 Nov;29(11):2985-93. doi: 10.1007/s11095-012-0809-2. Epub 2012 Jun 26. Review.

PMID:
22733149
19.

Recent developments in the chemical biology of epothilones.

Altmann KH.

Curr Pharm Des. 2005;11(13):1595-613. Review.

PMID:
15892665
20.

Update on tubulin-binding agents.

Attard G, Greystoke A, Kaye S, De Bono J.

Pathol Biol (Paris). 2006 Mar;54(2):72-84. Review.

PMID:
16545633
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk